Asthma-chronic obstructive pulmonary disease overlap: Results from a national-multicenter study.

Introduction: Patients with asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) have a greater disease burden than those with COPD or asthma alone. In this study, it was aimed to determine the prevalence, risk factors, and clinical features of ACO because there are limited national data in Türkiye.

Materials And Methods: The study was conducted in a cross-sectional design in nine tertiary-care hospitals.

A Simple Measure to Assess Hyperinflation and Air Trapping: 1-Forced Expiratory Volume in Three Second / Forced Vital Capacity.

Background: Several recent studies have suggested that 1 minus-forced expiratory volume expired in 3 seconds / forced vital capacity (1-FEV3/FVC) may be an indicator of distal airway obstruction and a promising measure to evaluate small airways dysfunction.

Aims: To investigate the associations of 1-FEV3/FVC with the spirometric measures and lung volumes that assess small airways dysfunction and reflects hyperinflation and air trapping.

Study Design: Retrospective cross-sectional study.

[Asthma-COPD overlap syndrome].

Asthma and chronic obstructive pulmonary disease (COPD) are common lung diseases characterized by chronic airway inflammation and airway obstruction. Among patient with COPD and asthma; there is a group of patients with an overlap between clinical, functional characteristics and airway inflammation patterns, named "Asthma-COPD Overlap Syndrome" (ACOS). ACOS is a syndrome characterized by reversible but persistant airflow limitation (postbronchodilator FEV1/FVC < 70%) which has some features of both asthma and COPD.

[Acute exacerbation in COPD and asthma].

Chronic obstructive pulmonary disease (COPD) and asthma are airway diseases with acute exacerbations. Natural course of both disease are affected by exacerbations. COPD exacerbations may be caused by infections and other causes; indoor and outdoor pollution, cardiovascular diseases, asthma-COPD overlap syndrome, COPD- obstructive sleep apnea syndrome, pulmonary embolism, gastro-oesophageal reflux, anxiety-depression, pulmonary hypertension.

Updates in Chronic Obstructive Pulmonary Disease for the Year 2014.

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in the world. Research conducted over the past decade has contributed much to our current knowledge of the pathogenesis and treatment of COPD. Additionally, an evolving literature has recently accumulated information about the management of COPD and also about exacerbations.

[Treatment of severe asthma: expert opinion].

Severe asthmatics account 10% of the all asthmatic population. Those asthmatics whose disease is inadequately controlled account for up to half of the cost for asthma, because they have more emergency room visits, more hospital admission and greater absenteeism from work. New therapeutic options were tried in those patients whose asthma was uncontrolled with standart high dose inhaled corticosteroid and long acting beta-2 agonsit combination therapy.

[Effects of inhaled corticosteroids/long-acting beta-2 agonist fix combinations in COPD].

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease characterized with progressive air flow limitation, and is expected to be the third leading cause of death until 2030 worldwide. The clinical trials in the last 10 years revealed that fix combinations (inhaled corticosteroids/long-acting beta-2 agonist; ICS/LABA) improve lung functions and quality of life, and reduced symptoms and exacerbation rates in patients with severe and very severe COPD.

[Inhaled corticosteroid/beta-2 agonist therapy in moderate COPD].

Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline defines moderate chronic obstructive pulmonary disease (COPD) as cases with postbronchodilator FEV(1) values between 80-50%. Guidelines list their expectations of COPD treatment as improvement in quality of life and functions, slowing functional progression, decreasing and treatment of exacerbations and complications and reduction in mortality. Guidelines, specifically the more commonly used GOLD guideline, recommends regular use of long acting bronchodilators alone or in combinations in symptomatic moderate COPD patients.

Pulmonary function in multiple sclerosis without any respiratory complaints.

Objectives: Pulmonary complications in severe multiple sclerosis (MS) are often seen secondary to respiratory muscle dysfunction. The development of respiratory muscle dysfunction and its association with disability during the course of MS is unknown. In our study, we investigated the predictive value of respiratory muscle functions and the change in forced vital capacity (Delta forced vital capacity [FVC]; FVC upright-FVC supine) to detect deterioration of respiratory muscle functions in the early phase of MS.

Plasma paraoxonase activities, lipoprotein oxidation, and trace element interaction in asthmatic patients.

Paraoxonase (PON1) protects low and high-density lipoproteins (LDL and HDL) against oxidation induced by reactive oxygen species formation facilitated by iron (Fe) and copper (Cu) ions. Plasma PON1, arylesterase, oxidized LDL (Ox-LDL), Cu, Fe, thiobarbituric acid-reactive substances (TBARS), lipid, lipoprotein, and apolipoprotein profile in bronchial asthma were determined and the relations among these parameters in different steps of asthma were interpreted. A total of 58 individuals, 30 asthmatics and 28 controls, were included into the scope of this study.

The relationship between pulmonary function tests, thorax HRCT, and quantitative ventilation-perfusion scintigraphy in chronic obstructive pulmonary disease.

We have evaluated the relationship between pulmonary function tests (PFT), thorax high resolution computed tomography (HRCT) images and quantitative ventilation-perfusion (V/Q) scintigraphic studies in 16 male patients (mean age 65.6 +/- 5.5 years) with chronic obstructive pulmonary disease (COPD).

The role of FEV6 in the detection of airway obstruction.

Objectives: There are recent reports regarding the use of forced expiratory volume in 6 s (FEV6) in place of forced expiratory vital capacity (FVC) in the detection of airway obstruction. We aimed to investigate the role of FEV6 in comparison with FVC in the evaluation of airway obstruction.

Methods: The pulmonary function tests (PFT) results of all 5114 patients, who had been tested in the pulmonary function laboratory between 1998 and 2003, were retrospectively analyzed to investigate the relationship between FEV6 and FVC.

[Videothoracoscopic lung biopsy in the diagnosis of interstitial lung disease].

Video-assisted thoracoscopic surgery (VATS) is a diagnostic method, used with increasing frequency in recent years, in the diagnosis of interstitial lung diseases. There are significant differences in the diagnosis of diseases which are diagnosed with clinical, biochemical and radiological investigation and with pathological evaluation of material obtained by VATS. In our study, five patients with different clinical and VATS guided pathological diagnosis, were analyzed.